The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of neoadjuvant lenvatinib plus pembrolizumab in Merkel cell carcinoma.
 
Andrew Brohl
Consulting or Advisory Role - Deciphera
Research Funding - Merck (Inst)
 
Vernon Sondak
Consulting or Advisory Role - Bristol-Myers Squibb; Genesis Drug Discovery & Development; Iovance Biotherapeutics; Merck/Schering Plough; Mural Oncology; Novartis; Sun Pharma
Research Funding - Neogene Therapeutics (Inst); Skyline Diagnostics (Inst); Turnstone Bio (Inst)
 
Evan Wuthrick
No Relationships to Disclose
 
Youngchul Kim
No Relationships to Disclose
 
Zeynep Eroglu
Consulting or Advisory Role - Incyte; Natera; Pfizer; Regeneron; Replimune; Sun Pharma
Research Funding - Boehringer Ingelheim (Inst); Pfizer (Inst)
 
Joseph Markowitz
Stock and Other Ownership Interests - Amdocs; Consolidated Edison
Consulting or Advisory Role - Newlink Genetics
Research Funding - Idera (Inst); Merck (Inst); Morphogenesis (Inst)
Patents, Royalties, Other Intellectual Property - Patent on development of Inhibitors for S100B (Inst); Pending patent on flow cytometry analysis system (Inst); Pending patent on the role of nitric oxide in melanoma. (Inst)
Other Relationship - Springer
 
Ahmad Tarhini
Consulting or Advisory Role - AstraZeneca; Bayer; BioNTech; Bristol-Myers Squibb; Clinigen Group; ConcertAI; Eisai; Genentech/Roche; Instil Bio; Merck; Nested; Novartis; Partner Therapeutics; Sanofi/Regeneron
Research Funding - Acrotech Biopharma (Inst); Agenus (Inst); Agenus (Inst); Bristol-Myers Squibb (Inst); Clinigen Group (Inst); Genentech/Roche (Inst); InflaRx (Inst); Merck (Inst); OncoSec (Inst); Pfizer (Inst); Sanofi/Regeneron (Inst); Scholar Rock (Inst)
 
Wenyi Fan
No Relationships to Disclose
 
Justin Martin
No Relationships to Disclose
 
Lymon Sneed
No Relationships to Disclose
 
Matthew Perez
No Relationships to Disclose
 
Amod Sarnaik
Honoraria - Clinical Education Alliance; Gerson Lehrman Group; Guidepoint Inc; Iovance Biotherapeutics; Iovance Biotherapeutics (Inst); Iovance Biotherapeutics (Inst); MJH Healthcare Holdings, LLC; Second City LLC; Society for Immunotherapy of Cancer
Research Funding - Genentech (Inst); Iovance Biotherapeutics (Inst); Provectus (Inst); Turnstone Bio (Inst)
Patents, Royalties, Other Intellectual Property - Compositions and methods for improving tumor-infiltrating lymphocytes for adoptive cell therapy, filed March 20, 2014 U.S. Patent Application No. 61/955,970 and second Application No. 61/973,002 (Inst); Culture of Tumor-infiltrating lymphocytes from tumor digest, filed March 24, 2021 US Patent Application No. 17/279,327 (Inst); Method of ex vivo enhancement of immune cell activity for cancer immunotherapy with a small molecule ablative compound, filed August 21, 2018 U.S. Patent Application No. 14/974,357; Rapid method for culture of tumor-infiltrating lymphocytes from core needle biopsies of solid tumors, filed January 2, 2018 U.S. Patent Application No. 62/612,915 (Inst); Tumor-infiltrating lymphocytes and stapled peptoid peptide hybrid peptidomimetics, filed October 11, 2018 U.S. Patent Application No. 16/157,174 (Inst)
Travel, Accommodations, Expenses - Bluprint Oncology Concepts; Iovance Biotherapeutics
 
Michael Harrington
No Relationships to Disclose
 
Rogerio Neves
No Relationships to Disclose
 
Ricardo Gonzalez
No Relationships to Disclose
 
Wayne Cruse
No Relationships to Disclose
 
Jonathan Zager
Stock and Other Ownership Interests - Johnson & Johnson/Janssen
Honoraria - Castle Biosciences; Delcath Systems; Merck; Merit Medical Systems; Sun Pharma
Consulting or Advisory Role - Castle Biosciences; Delcath Systems; Philogen
Speakers' Bureau - Merit Medical Systems; Pfizer; Sun Pharma
Research Funding - Castle Biosciences (Inst); Delcath Systems (Inst); NeraCare GmbH (Inst); Philogen (Inst); Provectus (Inst)
Patents, Royalties, Other Intellectual Property - US Patent # 11,779,698; US Patent 10,583,246
Expert Testimony - Bubalo Law; McGowan, Hood, Felder & Phillips, LLC
Travel, Accommodations, Expenses - Merck
 
Kenneth Tsai
Stock and Other Ownership Interests - Dimerix; NFlection Therapeutics
Consulting or Advisory Role - EMD Serono; NFLection Therapeutics; Sun Pharma; Verrica Pharmaceuticals; Voiant Clinical
Research Funding - FORMA Therapeutics; Incyte
Patents, Royalties, Other Intellectual Property - NFlection Therapeutics and Moffitt Cancer Center, John Kincaid, Kavita Sarin, Kenneth Y. Tsai, ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS, 046776-523P01US, 11/20/2019; UCSB, Samir Mitragotri, Byeong Hee Hwang, Nishit Doshi, Kenneth Tsai, Russell M. Lebovitz. COMPOSITIONS FOR SOLUBILIZING CELLS AND/OR TISSUE, United States, 13/432,978, 3/28/2012.
 
Nikhil Khushalani
Stock and Other Ownership Interests - Amarin Corporation; Asensus Surgical; Bellicum Pharmaceuticals
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bristol-Myers Squibb; Castle Biosciences; Genzyme; Immunocore; Incyte; Instil Bio; IO Biotech; Iovance Biotherapeutics; Jounce Therapeutics; Merck; NCCN/Pfizer; Nektar; Novartis; Regeneron; Replimune
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); GlaxoSmithKline (Inst); HUYA Bioscience International (Inst); IDEAYA Biosciences (Inst); Merck (Inst); Modulation Therapeutics (Inst); Novartis (Inst); Regeneron (Inst); Replimune (Inst)
Travel, Accommodations, Expenses - Castle Biosciences; Regeneron
Other Relationship - Bristol-Myers Squibb/Celgene; Nektar; Regeneron; Replimune; T-knife Therapeutics